Brooks Laboratories Ltd vs Lincoln Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Brooks Laboratories Ltd is ₹ 56.48 as of 30 Apr 15:30 . The P/E Ratio of Brooks Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Lincoln Pharmaceuticals Ltd changed from 7.2 on March 2021 to 13.4 on March 2025 . This represents a CAGR of 13.23% over 5 years The Market Cap of Brooks Laboratories Ltd changed from ₹ 153.53 crore on March 2021 to ₹ 317.37 crore on March 2025 . This represents a CAGR of 15.63% over 5 yearsThe Market Cap of Lincoln Pharmaceuticals Ltd changed from ₹ 449.4 crore on March 2021 to ₹ 1104 crore on March 2025 . This represents a CAGR of 19.71% over 5 years The revenue of Brooks Laboratories Ltd for the Dec '25 is ₹ 21.89 crore as compare to the Sep '25 revenue of ₹ 29.58 crore. This represent the decline of -26% The revenue of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 181.47 crore as compare to the Sep '25 revenue of ₹ 170.6 crore. This represent the growth of 6.37% The ebitda of Brooks Laboratories Ltd for the Dec '25 is ₹ 6.05 crore as compare to the Sep '25 ebitda of ₹ 8.65 crore. This represent the decline of -30.06% The ebitda of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 38.74 crore as compare to the Sep '25 ebitda of ₹ 32.66 crore. This represent the growth of 18.62% The net profit of Brooks Laboratories Ltd changed from ₹ -2.41 crore to ₹ 5.5 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Lincoln Pharmaceuticals Ltd changed from ₹ 23.67 crore to ₹ 28.6 crore over 7 quarters. This represents a CAGR of 11.42% The Dividend Payout of Brooks Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Lincoln Pharmaceuticals Ltd changed from 4.83 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of -1.94% over 5 years .

About Brooks Laboratories Ltd

Brooks Laboratories Limited was incorporated on January 23, 2002.
The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.
The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment.
It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes.
At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95.
All the assets and business of the erstwhile partnership were transferred to the Company.
The Company is engaged in the business of manufacturing and trading of pharmaceutical products.
The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others. The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982.
It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments.

FAQs for the comparison of Brooks Laboratories Ltd and Lincoln Pharmaceuticals Ltd

Which company has a larger market capitalization, Brooks Laboratories Ltd or Lincoln Pharmaceuticals Ltd?

Market cap of Brooks Laboratories Ltd is 166 Cr while Market cap of Lincoln Pharmaceuticals Ltd is 1,292 Cr

What are the key factors driving the stock performance of Brooks Laboratories Ltd and Lincoln Pharmaceuticals Ltd?

The stock performance of Brooks Laboratories Ltd and Lincoln Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Brooks Laboratories Ltd and Lincoln Pharmaceuticals Ltd?

As of May 4, 2026, the Brooks Laboratories Ltd stock price is INR ₹56.48. On the other hand, Lincoln Pharmaceuticals Ltd stock price is INR ₹645.4.

How do dividend payouts of Brooks Laboratories Ltd and Lincoln Pharmaceuticals Ltd compare?

To compare the dividend payouts of Brooks Laboratories Ltd and Lincoln Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.